{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:01:07Z","timestamp":1785135667468,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.pnpbp.2026.111783","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:49:45Z","timestamp":1781308185000},"page":"111783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clozapine and obsessive-compulsive symptoms: Integrating clinical outcomes, mechanisms, and precision psychiatry approaches"],"prefix":"10.1016","volume":"148","author":[{"given":"Gamze","family":"G\u00fcrcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravza Zeynep","family":"S\u0131lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pnpbp.2026.111783_bb0005","first-page":"439","article-title":"Emergence of obsessive compulsive symptoms during treatment with clozapine","volume":"53","author":"Baker","year":"1992","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111783_bb0010","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.euroneuro.2019.06.006","article-title":"A cross-sectional study of impact and clinical risk factors of antipsychotic-induced OCD","volume":"29","author":"Biria","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111783_bb0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/2045125311425971","article-title":"Does clozapine cause or worsen obsessive compulsive symptoms? An analysis and literature review","volume":"1","author":"Bleakley","year":"2011","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111783_bb0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-013-3137-2","article-title":"Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms","volume":"230","author":"Cai","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111783_bb0025","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.eurpsy.2004.09.022","article-title":"Obsessive\u2013compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders","volume":"19","author":"De Haan","year":"2004","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111783_bb0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.comppsych.2013.09.001","article-title":"Obsessive compulsive symptoms in patients with schizophrenia on clozapine and with obsessive compulsive disorder: a comparison study","volume":"55","author":"Doyle","year":"2014","journal-title":"Compr. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111783_bb0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1440-1819.2005.01362.x","article-title":"Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients","volume":"59","author":"Ertu\u011frul","year":"2005","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"16","key":"10.1016\/j.pnpbp.2026.111783_bb0040","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1017\/S003329171800017X","article-title":"Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia","volume":"48","author":"Fernandez-Egea","year":"2018","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0045","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11920-014-0510-8","article-title":"Second-generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature","volume":"16","author":"Fonseka","year":"2014","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.psychres.2016.09.031","article-title":"Induced obsessive compulsive symptoms (OCS) in schizophrenia patients under atypical antipsychotics (AAPs): review and hypotheses","volume":"30","author":"Grillault Laroche","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ajp.2015.05.002","article-title":"Relationship of obsessive compulsive symptoms\/disorder with clozapine: a retrospective study from a multispeciality tertiary care centre","volume":"15","author":"Grover","year":"2015","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113665","article-title":"Clinical risk factors, phenomenology and the impact of clozapine-induced obsessive compulsive symptoms","volume":"296","author":"G\u00fcrcan","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13041-020-00621-5","article-title":"Clozapine generates obsessive compulsive disorder-like behavior in mice","volume":"13","author":"Kang","year":"2020","journal-title":"Mol. Brain"},{"key":"10.1016\/j.pnpbp.2026.111783_bb0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pnpbp.2012.05.011","article-title":"Symptom structure of antipsychotic-induced obsessive compulsive symptoms in schizophrenia patients","volume":"39","author":"Kim","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111783_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1503\/jpn.180087","article-title":"Clozapine-induced obsessive\u2013compulsive symptoms: mechanisms and treatment","volume":"44","author":"Kim","year":"2019","journal-title":"J. Psychiatry Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111783_bb0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000505876","article-title":"Clozapine-associated obsessive-compulsive symptoms and their management: a systematic review and analysis of 107 reported cases","volume":"89","author":"Kim","year":"2020","journal-title":"Psychother. Psychosom."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111783_bb0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/PRA.0000000000000470","article-title":"Integration of clozapine-associated harm obsessions into cognitive behavioral conceptualization and treatment planning for thought broadcasting: a case study","volume":"26","author":"Kopelovich","year":"2020","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0090","article-title":"Psychosis or obsessions? Clozapine associated with worsening obsessive-compulsive symptoms","volume":"2016","author":"Leung","year":"2016","journal-title":"Case Rep. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111783_bb0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","article-title":"Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms","volume":"28","author":"Lin","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0100","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2174\/138161210790361416","article-title":"Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex","volume":"16","author":"Lopez-Gil","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","article-title":"Obsessive\u2013compulsive symptoms induced by atypical antipsychotics: a review of the reported cases","volume":"27","author":"Lykouras","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111783_bb0110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4088\/JCP.v68n0408","article-title":"De novo emergence of obsessive\u2013compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study","volume":"68","author":"Mahendran","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111783_bb0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12888-024-06466-9","article-title":"Prevalence of obsessive-compulsive symptoms in patients with schizophrenia treated with clozapine: a scoping review","volume":"25","author":"Moreno Tarazona","year":"2025","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111783_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00406-023-01593-y","article-title":"Polygenic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia","volume":"274","author":"Morgenroth","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0269881108089582","article-title":"Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern","volume":"23","author":"Mukhopadhaya","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111783_bb0130","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1017\/S003329172100492X","article-title":"Clozapine-related obsessive\u2013compulsive symptoms and their impact on wellbeing: a naturalistic longitudinal study","volume":"53","author":"Parkin","year":"2023","journal-title":"Psychol. Med."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111783_bb0135","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1176\/ajp.155.11.1626f","article-title":"Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior","volume":"155","author":"Rahman","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111783_bb0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-2004-815525","article-title":"Clozapine in the treatment of obsessive\u2013compulsive symptoms in schizophrenia patients: a case series study","volume":"37","author":"Reznik","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2026.111783_bb0145","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ajmg.b.31242","article-title":"Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms","volume":"156B","author":"Ryu","year":"2011","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0150","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.comppsych.2008.11.005","article-title":"Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol","volume":"50","author":"S\u00e1","year":"2009","journal-title":"Compr. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111783_bb0155","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4088\/JCP.11m07164","article-title":"Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients","volume":"73","author":"Scheltema-Beduin","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111783_bb0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157015912799362724","article-title":"Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review","volume":"10","author":"Schirmbeck","year":"2012","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2013.00099","article-title":"Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors","volume":"4","author":"Schirmbeck","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0170","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1017\/S0033291711000419","article-title":"Antiserotonergic antipsychotics are associated with obsessive\u2013compulsive symptoms in schizophrenia","volume":"41","author":"Schirmbeck","year":"2011","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1503\/jpn.140021","article-title":"Increased orbitofrontal cortex activation associated with \u201cpro-obsessive\u201d antipsychotic treatment in patients with schizophrenia","volume":"40","author":"Schirmbeck","year":"2015","journal-title":"J. Psychiatry Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111783_bb0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sjpmh.2023.10.001","article-title":"Obsessive-compulsive symptoms and disorder in clozapine-treated schizophrenia","volume":"18","author":"Seow","year":"2025","journal-title":"Span. J. Psychiatry Ment. Health"},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2026.111783_bb0185","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.schres.2013.10.033","article-title":"The obsessive compulsive spectrum in schizophrenia: a meta-analysis and meta-regression exploring prevalence rates","volume":"152","author":"Swets","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0190","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1476-5381.2011.01638.x","article-title":"Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes","volume":"165","author":"Tanahashi","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111783_bb0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40263-017-0411-6","article-title":"Clozapine for treatment-resistant schizophrenia: still the gold standard?","volume":"31","author":"Taylor","year":"2017","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111783_bb0200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/13651501.2014.943243","article-title":"Obsessive-compulsive symptoms are related to lower quality of life in patients with schizophrenia","volume":"18","author":"\u00dc\u00e7ok","year":"2014","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111783_bb0205","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1192\/bja.2020.57","article-title":"Pharmacological management of comorbid obsessive\u2013compulsive disorder and chronic non-affective psychosis","volume":"27","author":"Udo","year":"2021","journal-title":"BJPsych Adv."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111783_bb0210","first-page":"60","article-title":"Clozapine-induced obsessive-compulsive symptoms and augmentation with clonazepam: risks and rationales","volume":"34","author":"\u00dcnler","year":"2023","journal-title":"Turk. Psikiyatri Derg."},{"key":"10.1016\/j.pnpbp.2026.111783_bb0215","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/317980","article-title":"Comorbid obsessive-compulsive symptoms in schizophrenia: insight into pathomechanisms facilitates treatment","volume":"2014","author":"Zink","year":"2014","journal-title":"Adv. Med."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626001818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626001818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:22:16Z","timestamp":1785133336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626001818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S0278584626001818"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111783","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine and obsessive-compulsive symptoms: Integrating clinical outcomes, mechanisms, and precision psychiatry approaches","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111783"}}